

IFW

Attorney Docket No.: 4341.224-US

PATENT
FAX RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 07 2007

OFFICE OF PETITIONS

In re Application of: Markussen et al.

Serial No.: 10/620,651

Group Art Unit: 1646

Filed: July 16, 2003

Examiner: Chandra, Gyan

For: Insulin Derivatives

CERTIFICATE OF FACSIMILE TRANSMISSION
571-273-0025Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Petition to Correct Inventorship Under 37 CFR 1.48(b) (in duplicate)

was sent to the United States Patent and Trademark Office by telefax to the attention of Office of Petitions, fax number (571)-273-0025.

Respectfully submitted,

Date: May 7, 2007

/Csaba Attila Szakolczai/
Csaba Attila Szakolczai
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Attorney Docket No.: 4341.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Markussen et al.

Application No.: 10/620,651

Group Art Unit: 1646

Filed: July 16, 2003

Examiner: Chandra, Gyan

For: Insulin Derivatives

PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

Applicants hereby petition to change the inventorship in the above-captioned application to delete Jakob Brandt as an inventor.


The correct inventors were named in the application when filed. However, the prosecution of the application has resulted in the amendment and cancellation of claims so that less than all of the originally named inventors are the actual inventors of the invention being claimed in the application.

Applicants therefore have deleted Jakob Brandt as an inventor in this application.

Please charge the required fee under 37 C.F.R. 1.17 (i), estimated to be \$130.00, to Novo Nordisk Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 7, 2007


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 4341.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Markussen et al.

Application No.: 10/620,651

Group Art Unit: 1646

Filed: July 16, 2003

Examiner: Chandra, Gyan

For: Insulin Derivatives

PETITION TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

Applicants hereby petition to change the inventorship in the above-captioned application to delete Jakob Brandt as an inventor.


The correct inventors were named in the application when filed. However, the prosecution of the application has resulted in the amendment and cancellation of claims so that less than all of the originally named inventors are the actual inventors of the invention being claimed in the application.

Applicants therefore have deleted Jakob Brandt as an inventor in this application.

Please charge the required fee under 37 C.F.R. 1.17 (i), estimated to be \$130.00, to Novo Nordisk Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 7, 2007


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE